Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201212100 Principal Investigator: Bartlett, Nancy
Title: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion
Phase: II Disease Site: Non-Hodgkin's Lymphoma
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to test whether or not the investigational study drug, PCI-32765(ibrutinib) works and is safe in patients with CLL / SLL with 17p deletion.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)